PHILADELPHIA--(BUSINESS WIRE)--Hemispherx Biopharma, Inc. (AMEX: HEB) announced today the first scientific publication (Journal of Immunology, April 2007) that explains the unique therapeutic properties of its proprietary experimental therapeutic, Ampligen® (Poly I : Poly C12U), a double-stranded RNA being tested as a monotherapy for Chronic Fatigue Syndrome and as an adjuvant to other drugs and vaccines.
